Skip to content

To evaluate the value of metagenomic second generation sequencing (mNGS) drug resistance gene detection in the etiological detection of severe pneumonia caused by multi-drug resistant bacteria in ICU

To evaluate the value of metagenomic second generation sequencing (mNGS) drug resistance gene detection in the etiological detection of severe pneumonia caused by multi-drug resistant bacteria in ICU

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072249
Enrollment
Unknown
Registered
2023-06-07
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Interventions

Case series:N/A

Sponsors

Union Jiangbei Hospital,Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients aged 18-80 years with severe pulmonary infection and pneumonia related clinical manifestations: recent cough, sputum, or exacerbation of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, and hemoptysis ,Fever ,Signs of lung consolidation and/or pulmonary auscultation of moist rales ,Peripheral blood leukocytes >10*109 / L or <4 *109 / L, with or without nuclear shift to the left. 2) The diagnosis of severe pneumonia was based on IDSA/ATS. 3) Patients who agree to undergo mNGS testing.

Exclusion criteria

Exclusion criteria: 1) non-infectious pneumonia 2) Severe immunosuppression 3) Active tuberculosis or end-stage disease 4) There is a "DNR" signature 5) Patients with a history of antibiotic or other drug allergies 6) Pregnant women 7) Study other patients whom the doctor deems unsuitable for the study 8) Do not agree with mNGS detection

Design outcomes

Primary

MeasureTime frame
Positive rate of detection;Day 28 mortality;

Secondary

MeasureTime frame
Total hospitalization expenses;MODS incidence rate;Incidence of septic shock;Total hospitalization time (days);ICU hospitalization time (days);Mechanical ventilation time (h);Use of vasoactive drugs;

Countries

China

Contacts

Public ContactJun Guo

Union Jiangbei Hospital,Huazhong University of Science and Technology

625246269@qq.com+86 189 0863 6226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026